Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlledtrial
Identifieur interne : 005D43 ( Main/Exploration ); précédent : 005D42; suivant : 005D44Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlledtrial
Auteurs : Axel Hauschild [Allemagne] ; Jean-Jacques Grob [France] ; Lev V. Demidov [Russie] ; Thomas Jouary [France] ; Ralf Gutzmer [Allemagne] ; Michael Millward [Australie] ; Piotr Rutkowski [Pologne] ; Christian U. Blank [Pays-Bas] ; Wilson H. Jr Miller [Canada] ; Eckhart Kaempgen [Allemagne] ; Salvador Martin-Algarra [Espagne] ; Bogusiawa Karaszewska [Pologne] ; Cornelia Mauch [Allemagne] ; Vanna Chiarion-Sileni [Italie] ; Anne-Marie Martin [États-Unis] ; Suzanne Swann [États-Unis] ; Patricia Haney [États-Unis] ; Beloo Mirakhur [États-Unis] ; Mary E. Guckert [États-Unis] ; Vicki Goodman [États-Unis] ; Paul B. Chapman [États-Unis]Source :
- Lancet : (British edition) [ 0140-6736 ] ; 2012.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Médecine.
English descriptors
- KwdEn :
Abstract
Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAV600-mutated metastatic melanoma. We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma. Methods We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011. This report is based on a data cutoff date of Dec 19, 2011. Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-positive melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 intravenously every 3 weeks). Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c). The primary endpoint was investigator-assessed progression-free survival and was analysed by intention to treat; safety was assessed per protocol. This study is registered with ClinicalTrials.gov, number NCT01227889. Findings Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients). Median progression-free survival was 5.1 months for dabrafenib and 2.7 months for dacarbazine, with a hazard ratio (HR) of 0.30 (95% CI 0.18-0.51; p<0 0001). At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomised treatment. Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine. The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia. Grade 3-4 adverse events were uncommon in both groups. Interpretation Dabrafenib significantly improved progression-free survival compared with dacarbazine. Funding GlaxoSmithKline.
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Italie, Pays-Bas, Pologne, Russie, États-Unis
- Aquitaine, Bavière, District de Moyenne-Franconie, District fédéral central, Hollande-Septentrionale, Nouvelle-Aquitaine, Provence-Alpes-Côte d'Azur, Schleswig-Holstein
- Amsterdam, Bordeaux, Erlangen, Kiel, Marseille, Moscou
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001208
- to stream PascalFrancis, to step Curation: 004D09
- to stream PascalFrancis, to step Checkpoint: 001222
- to stream Main, to step Merge: 006057
- to stream Main, to step Curation: 005D43
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlledtrial</title><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University Hospital, Schleswig-Holstein, Department of Dermatology</s1><s2>Kiel</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, HôpitalTimone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Demidov, Lev V" sort="Demidov, Lev V" uniqKey="Demidov L" first="Lev V." last="Demidov">Lev V. Demidov</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>NN Blokhin Russian Cancer Research Centre</s1><s2>Moscow</s2><s3>RUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Jouary, Thomas" sort="Jouary, Thomas" uniqKey="Jouary T" first="Thomas" last="Jouary">Thomas Jouary</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Skin Cancer Unit, Dermatology Department, Hôpital Saint André</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Gutzmer, Ralf" sort="Gutzmer, Ralf" uniqKey="Gutzmer R" first="Ralf" last="Gutzmer">Ralf Gutzmer</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Dermatology and Allergy, Skin Cancer Centre, Hannover Medical School</s1><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Hannover Medical School</wicri:noRegion><wicri:noRegion>Department of Dermatology and Allergy, Skin Cancer Centre, Hannover Medical School</wicri:noRegion></affiliation></author><author><name sortKey="Millward, Michael" sort="Millward, Michael" uniqKey="Millward M" first="Michael" last="Millward">Michael Millward</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Sir Charles Gairdner Hospital and University of Western Australia</s1><s2>Perth, WA</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Sir Charles Gairdner Hospital and University of Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology</s1><s2>Warsaw</s2><s3>POL</s3><sZ>7 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Blank, Christian U" sort="Blank, Christian U" uniqKey="Blank C" first="Christian U." last="Blank">Christian U. Blank</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Division of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL)</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Miller, Wilson H Jr" sort="Miller, Wilson H Jr" uniqKey="Miller W" first="Wilson H. Jr" last="Miller">Wilson H. Jr Miller</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital</s1><s2>Montreal, QC</s2><s3>CAN</s3><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, QC</wicri:noRegion></affiliation></author><author><name sortKey="Kaempgen, Eckhart" sort="Kaempgen, Eckhart" uniqKey="Kaempgen E" first="Eckhart" last="Kaempgen">Eckhart Kaempgen</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen</s1><s2>Erlangen</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><settlement type="city">Erlangen</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Moyenne-Franconie</region></placeName></affiliation></author><author><name sortKey="Martin Algarra, Salvador" sort="Martin Algarra, Salvador" uniqKey="Martin Algarra S" first="Salvador" last="Martin-Algarra">Salvador Martin-Algarra</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Medical Oncology, Clínica Universidad de Navarra</s1><s2>Pamplona</s2><s3>ESP</s3><sZ>11 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Karaszewska, Bogusiawa" sort="Karaszewska, Bogusiawa" uniqKey="Karaszewska B" first="Bogusiawa" last="Karaszewska">Bogusiawa Karaszewska</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Przychodnia Lekarska KOMED</s1><s2>Konin</s2><s3>POL</s3><sZ>12 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Przychodnia Lekarska KOMED</wicri:noRegion></affiliation></author><author><name sortKey="Mauch, Cornelia" sort="Mauch, Cornelia" uniqKey="Mauch C" first="Cornelia" last="Mauch">Cornelia Mauch</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne</s1><s2>Cologne</s2><s3>DEU</s3><sZ>13 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>University Hospital Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Melanoma and Skin Cancer Unit, Istituto Oncologico Veneto</s1><s2>Padova</s2><s3>ITA</s3><sZ>14 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Martin, Anne Marie" sort="Martin, Anne Marie" uniqKey="Martin A" first="Anne-Marie" last="Martin">Anne-Marie Martin</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Swann, Suzanne" sort="Swann, Suzanne" uniqKey="Swann S" first="Suzanne" last="Swann">Suzanne Swann</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Haney, Patricia" sort="Haney, Patricia" uniqKey="Haney P" first="Patricia" last="Haney">Patricia Haney</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Mirakhur, Beloo" sort="Mirakhur, Beloo" uniqKey="Mirakhur B" first="Beloo" last="Mirakhur">Beloo Mirakhur</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Guckert, Mary E" sort="Guckert, Mary E" uniqKey="Guckert M" first="Mary E." last="Guckert">Mary E. Guckert</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Goodman, Vicki" sort="Goodman, Vicki" uniqKey="Goodman V" first="Vicki" last="Goodman">Vicki Goodman</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Chapman, Paul B" sort="Chapman, Paul B" uniqKey="Chapman P" first="Paul B." last="Chapman">Paul B. Chapman</name><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Memorial Sloan-Kettering Cancer Center</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0318582</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0318582 INIST</idno><idno type="RBID">Pascal:12-0318582</idno><idno type="wicri:Area/PascalFrancis/Corpus">001208</idno><idno type="wicri:Area/PascalFrancis/Curation">004D09</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001222</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001222</idno><idno type="wicri:doubleKey">0140-6736:2012:Hauschild A:dabrafenib:in:braf</idno><idno type="wicri:Area/Main/Merge">006057</idno><idno type="wicri:Area/Main/Curation">005D43</idno><idno type="wicri:Area/Main/Exploration">005D43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlledtrial</title><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>University Hospital, Schleswig-Holstein, Department of Dermatology</s1><s2>Kiel</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, HôpitalTimone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Demidov, Lev V" sort="Demidov, Lev V" uniqKey="Demidov L" first="Lev V." last="Demidov">Lev V. Demidov</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>NN Blokhin Russian Cancer Research Centre</s1><s2>Moscow</s2><s3>RUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Jouary, Thomas" sort="Jouary, Thomas" uniqKey="Jouary T" first="Thomas" last="Jouary">Thomas Jouary</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Skin Cancer Unit, Dermatology Department, Hôpital Saint André</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Gutzmer, Ralf" sort="Gutzmer, Ralf" uniqKey="Gutzmer R" first="Ralf" last="Gutzmer">Ralf Gutzmer</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Dermatology and Allergy, Skin Cancer Centre, Hannover Medical School</s1><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Hannover Medical School</wicri:noRegion><wicri:noRegion>Department of Dermatology and Allergy, Skin Cancer Centre, Hannover Medical School</wicri:noRegion></affiliation></author><author><name sortKey="Millward, Michael" sort="Millward, Michael" uniqKey="Millward M" first="Michael" last="Millward">Michael Millward</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Sir Charles Gairdner Hospital and University of Western Australia</s1><s2>Perth, WA</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Sir Charles Gairdner Hospital and University of Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology</s1><s2>Warsaw</s2><s3>POL</s3><sZ>7 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Blank, Christian U" sort="Blank, Christian U" uniqKey="Blank C" first="Christian U." last="Blank">Christian U. Blank</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Division of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL)</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Miller, Wilson H Jr" sort="Miller, Wilson H Jr" uniqKey="Miller W" first="Wilson H. Jr" last="Miller">Wilson H. Jr Miller</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital</s1><s2>Montreal, QC</s2><s3>CAN</s3><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, QC</wicri:noRegion></affiliation></author><author><name sortKey="Kaempgen, Eckhart" sort="Kaempgen, Eckhart" uniqKey="Kaempgen E" first="Eckhart" last="Kaempgen">Eckhart Kaempgen</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen</s1><s2>Erlangen</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><settlement type="city">Erlangen</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Moyenne-Franconie</region></placeName></affiliation></author><author><name sortKey="Martin Algarra, Salvador" sort="Martin Algarra, Salvador" uniqKey="Martin Algarra S" first="Salvador" last="Martin-Algarra">Salvador Martin-Algarra</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Medical Oncology, Clínica Universidad de Navarra</s1><s2>Pamplona</s2><s3>ESP</s3><sZ>11 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Karaszewska, Bogusiawa" sort="Karaszewska, Bogusiawa" uniqKey="Karaszewska B" first="Bogusiawa" last="Karaszewska">Bogusiawa Karaszewska</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Przychodnia Lekarska KOMED</s1><s2>Konin</s2><s3>POL</s3><sZ>12 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Przychodnia Lekarska KOMED</wicri:noRegion></affiliation></author><author><name sortKey="Mauch, Cornelia" sort="Mauch, Cornelia" uniqKey="Mauch C" first="Cornelia" last="Mauch">Cornelia Mauch</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne</s1><s2>Cologne</s2><s3>DEU</s3><sZ>13 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>University Hospital Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Melanoma and Skin Cancer Unit, Istituto Oncologico Veneto</s1><s2>Padova</s2><s3>ITA</s3><sZ>14 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Martin, Anne Marie" sort="Martin, Anne Marie" uniqKey="Martin A" first="Anne-Marie" last="Martin">Anne-Marie Martin</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Swann, Suzanne" sort="Swann, Suzanne" uniqKey="Swann S" first="Suzanne" last="Swann">Suzanne Swann</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Haney, Patricia" sort="Haney, Patricia" uniqKey="Haney P" first="Patricia" last="Haney">Patricia Haney</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Mirakhur, Beloo" sort="Mirakhur, Beloo" uniqKey="Mirakhur B" first="Beloo" last="Mirakhur">Beloo Mirakhur</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Guckert, Mary E" sort="Guckert, Mary E" uniqKey="Guckert M" first="Mary E." last="Guckert">Mary E. Guckert</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Goodman, Vicki" sort="Goodman, Vicki" uniqKey="Goodman V" first="Vicki" last="Goodman">Vicki Goodman</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>GlaxoSmithKline</s1><s2>Collegeville, PA</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>GlaxoSmithKline</wicri:noRegion></affiliation></author><author><name sortKey="Chapman, Paul B" sort="Chapman, Paul B" uniqKey="Chapman P" first="Paul B." last="Chapman">Paul B. Chapman</name><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Memorial Sloan-Kettering Cancer Center</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Lancet : (British edition)</title><title level="j" type="abbreviated">Lancet : (Br. ed.)</title><idno type="ISSN">0140-6736</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Lancet : (British edition)</title><title level="j" type="abbreviated">Lancet : (Br. ed.)</title><idno type="ISSN">0140-6736</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>BRAF Gene</term><term>C-Onc gene</term><term>Label</term><term>Malignant melanoma</term><term>Medicine</term><term>Metastasis</term><term>Metastatic</term><term>Multicenter study</term><term>Mutation</term><term>Phase</term><term>Protooncogene</term><term>Randomization</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Mélanome malin</term><term>Protooncogène</term><term>Gène onc cellulaire</term><term>Mutation</term><term>Métastase</term><term>Stade avancé</term><term>Métastatique</term><term>Etude multicentrique</term><term>Etiquette</term><term>Phase</term><term>Randomisation</term><term>Médecine</term><term>Gène BRAF</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médecine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRA<sup>V600</sup>-mutated metastatic melanoma. We studied the efficacy of dabrafenib in patients with BRAF<sup>V600E</sup>-mutated metastatic melanoma. Methods We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011. This report is based on a data cutoff date of Dec 19, 2011. Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAF<sup>V600E</sup> mutation-positive melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m<sup>2</sup> intravenously every 3 weeks). Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c). The primary endpoint was investigator-assessed progression-free survival and was analysed by intention to treat; safety was assessed per protocol. This study is registered with ClinicalTrials.gov, number NCT01227889. Findings Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients). Median progression-free survival was 5.1 months for dabrafenib and 2.7 months for dacarbazine, with a hazard ratio (HR) of 0.30 (95% CI 0.18-0.51; p<0 0001). At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomised treatment. Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine. The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia. Grade 3-4 adverse events were uncommon in both groups. Interpretation Dabrafenib significantly improved progression-free survival compared with dacarbazine. Funding GlaxoSmithKline.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Pologne</li><li>Russie</li><li>États-Unis</li></country><region><li>Aquitaine</li><li>Bavière</li><li>District de Moyenne-Franconie</li><li>District fédéral central</li><li>Hollande-Septentrionale</li><li>Nouvelle-Aquitaine</li><li>Provence-Alpes-Côte d'Azur</li><li>Schleswig-Holstein</li></region><settlement><li>Amsterdam</li><li>Bordeaux</li><li>Erlangen</li><li>Kiel</li><li>Marseille</li><li>Moscou</li></settlement></list><tree><country name="Allemagne"><region name="Schleswig-Holstein"><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name></region><name sortKey="Gutzmer, Ralf" sort="Gutzmer, Ralf" uniqKey="Gutzmer R" first="Ralf" last="Gutzmer">Ralf Gutzmer</name><name sortKey="Kaempgen, Eckhart" sort="Kaempgen, Eckhart" uniqKey="Kaempgen E" first="Eckhart" last="Kaempgen">Eckhart Kaempgen</name><name sortKey="Mauch, Cornelia" sort="Mauch, Cornelia" uniqKey="Mauch C" first="Cornelia" last="Mauch">Cornelia Mauch</name></country><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name></region><name sortKey="Jouary, Thomas" sort="Jouary, Thomas" uniqKey="Jouary T" first="Thomas" last="Jouary">Thomas Jouary</name></country><country name="Russie"><region name="District fédéral central"><name sortKey="Demidov, Lev V" sort="Demidov, Lev V" uniqKey="Demidov L" first="Lev V." last="Demidov">Lev V. Demidov</name></region></country><country name="Australie"><noRegion><name sortKey="Millward, Michael" sort="Millward, Michael" uniqKey="Millward M" first="Michael" last="Millward">Michael Millward</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name></noRegion><name sortKey="Karaszewska, Bogusiawa" sort="Karaszewska, Bogusiawa" uniqKey="Karaszewska B" first="Bogusiawa" last="Karaszewska">Bogusiawa Karaszewska</name></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Blank, Christian U" sort="Blank, Christian U" uniqKey="Blank C" first="Christian U." last="Blank">Christian U. Blank</name></region></country><country name="Canada"><noRegion><name sortKey="Miller, Wilson H Jr" sort="Miller, Wilson H Jr" uniqKey="Miller W" first="Wilson H. Jr" last="Miller">Wilson H. Jr Miller</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Martin Algarra, Salvador" sort="Martin Algarra, Salvador" uniqKey="Martin Algarra S" first="Salvador" last="Martin-Algarra">Salvador Martin-Algarra</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Martin, Anne Marie" sort="Martin, Anne Marie" uniqKey="Martin A" first="Anne-Marie" last="Martin">Anne-Marie Martin</name></noRegion><name sortKey="Chapman, Paul B" sort="Chapman, Paul B" uniqKey="Chapman P" first="Paul B." last="Chapman">Paul B. Chapman</name><name sortKey="Goodman, Vicki" sort="Goodman, Vicki" uniqKey="Goodman V" first="Vicki" last="Goodman">Vicki Goodman</name><name sortKey="Guckert, Mary E" sort="Guckert, Mary E" uniqKey="Guckert M" first="Mary E." last="Guckert">Mary E. Guckert</name><name sortKey="Haney, Patricia" sort="Haney, Patricia" uniqKey="Haney P" first="Patricia" last="Haney">Patricia Haney</name><name sortKey="Mirakhur, Beloo" sort="Mirakhur, Beloo" uniqKey="Mirakhur B" first="Beloo" last="Mirakhur">Beloo Mirakhur</name><name sortKey="Swann, Suzanne" sort="Swann, Suzanne" uniqKey="Swann S" first="Suzanne" last="Swann">Suzanne Swann</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0318582
|texte= Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlledtrial
}}
| This area was generated with Dilib version V0.6.33. |  |